- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00887835
A Post-Market Study of Transfacet Lumbar Spine Fixation and Fusion Utilizing the PERPOS™ PLS System
April 25, 2012 updated by: Interventional Spine, Inc.
The purpose of this study is to utilize the PERPOS™ PLS System for transfacet lumbar spine fixation to evaluate its effect on patients' level of pain, procedural complications and functional status.
Study Overview
Detailed Description
The PERPOS™ PLS System involves a minimally invasive, percutaneous implant procedure via a small incision.
The PERPOS™ PLS is intended for lumbar bilateral facet fixation, with or without bone graft, at single or multiple levels from L1 to S1.
Study Type
Interventional
Phase
- Not Applicable
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 85 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Females and males between 18 and 85
Must have lumbar facet disease confirmed by:
- Documented pain relief with controlled lumbar facet block using local anesthetic or steroid administration; AND
- MRI or CT scan, with or without bone scan, obtained within 3 months of enrollment, confirming arthritic facet joints OR, must have lumbar facet disease (as confirmed above) and are contra-indicated for steroid injections, or non-compliant with conservative pain management treatments, or wish to avoid the side-effects of steroids or prescriptive pain medication treatment
- Must score at least 4 on a 10-point Visual Analog Scale (VAS) for back pain
- Must score at least 40% on the Oswestry Disability Index.
- Must have less than 50% disc height loss
- Must have no greater than Grade I spondylolisthesis demonstrated on flexion and extension lumbar radiographs taken within 2 months of enrollment
- Willing and able to comply with the requirements of the protocol including follow-up requirements
- Willing and able to sign a study specific informed consent.
Exclusion Criteria:
- Are within the first two PERPOS PLS System utilization experience of the investigator
- Have severe facet degeneration, radiographic findings of severe facet joint disease, degeneration of misshapen facet(s) or structural anomalies at the target fusion level that would preclude proper placement of the BONE-LOK Implant.
- Have evidenced malingering behavior related to workman's compensation claims
- Have had any significant prior intervention (greater than an injection) in the facet joint to be treated, or within two (2) levels above or two (2) levels below the facet joint to be treated
- Have had prior instrumentation of involved vertebrae at any time
- Have osteoporotic bone at the lumbar spine level to be treated based on the SCORE (Simple Calculated Osteoporosis Risk Estimation) screening questionnaire, (or a DEXA bone density measured T score <-1.0.).
- Have scoliosis with lateral angulation >20 degrees
- Have an active malignancy: A subject with a history of any invasive malignancy (except non-melanoma skin cancer), unless s/he has been treated with curative intent and there have been no clinical signs or symptoms of malignancy for at least 5 years.
- Have a cyst in the canal associated with the facet
- Have neurologic deficit bowel or bladder dysfunction
- Have spinal canal or neural foramen compromise
- Have an infection (local or systemic)
- Have myelopathy
- Have abnormal coagulation time
- Have been or will be on anticoagulation therapy within 10 days of the study procedure
- Have radiculopathy
- Have cord compression or canal compromise requiring surgery for decompression
- Have disabling back pain secondary to another cause
- Have COPD that poses anesthesia risk
- Have severe cardiopulmonary deficiencies
- Have narcotic dependence or >90 days of narcotic pain medications
- Are morbidly obese (BMI >40)
- Have uncontrolled diabetes
- Have known allergies to implant materials, e.g., titanium.
- Are currently pregnant or lactating or considering becoming pregnant during the follow-up period
- Have been involved in an investigational drug or device study within the previous 30 days
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: PERPOS™ PLS
Minimally invasive transfacet fixation with PERPOS™ PLS as an aid to fusion
|
To stabilize the spine as an aid to fusion through bilateral immobilization of the facet joints.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in Oswestry Disability Index and Visual Analogue Scale
Time Frame: 1 year
|
1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2009
Primary Completion (ANTICIPATED)
October 1, 2010
Study Registration Dates
First Submitted
April 23, 2009
First Submitted That Met QC Criteria
April 23, 2009
First Posted (ESTIMATE)
April 24, 2009
Study Record Updates
Last Update Posted (ESTIMATE)
April 27, 2012
Last Update Submitted That Met QC Criteria
April 25, 2012
Last Verified
April 1, 2009
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- PLS-007-FUS
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lumbar Facet Disease
-
University of UtahActive, not recruiting
-
Complejo Hospitalario Universitario de GranadaUnknownFacet Joint Pain | Facet Syndrome of Lumbar Spine | Facet Joints; DegenerationSpain
-
Military University Hospital, PragueUniversity Hospital, MotolRecruitingDegenerative Disc Disease | Back Pain Lower Back Chronic | Facet Joint Arthropathy | Facet Syndrome of Lumbar SpineCzechia
-
Ain Shams UniversityCompletedLumbar Facet Joint SyndromeEgypt
-
Mansoura UniversityTanta UniversityCompletedFacet Syndrome of Lumbar SpineEgypt
-
Instituto de Investigación Hospital Universitario...CompletedLumbar Facet Joint Pain | Lumbar Medial Branch NeurotomySpain
-
FUSMobile Inc.Active, not recruitingFacet Syndrome of Lumbar SpineUnited States
-
FUSMobile Inc.Active, not recruitingFacet Syndrome of Lumbar SpineCanada
-
Stanford UniversityWithdrawnLumbar Facet Joint PainUnited States
-
Mehul DesaiHalyard HealthUnknownLumbar Facet Joint PainUnited States
Clinical Trials on PERPOS™ PLS
-
University Hospital of SplitUniversity of LiverpoolCompletedHealth Knowledge, Attitudes, PracticeCroatia
-
University of Split, School of MedicineCompletedHealth Knowledge, Attitudes, PracticeCroatia
-
University Hospital of SplitUniversity of LiverpoolCompletedHealth Knowledge, Attitudes, PracticeCroatia
-
Taipei Medical University HospitalCompleted
-
University Hospital of SplitCroatian Science FoundationCompletedUnderstanding Cochrane Systematic ReviewsCroatia
-
University of LimerickCompleted
-
BaroNova, Inc.Completed
-
London Health Sciences CentreUniversity of Western Ontario, Canada; Synaptive MedicalUnknownBrain Damage, Chronic | Cerebellar Cognitive Affective Syndrome | Cerebellar Mutism
-
Asklepios Kliniken Hamburg GmbHUniversity of KielCompletedAirway Management | Laryngeal Mask Airway | Fibreoptic Intubation
-
Andrew ParrentUniversity of Western Ontario, Canada; Synaptive MedicalUnknownTemporal Lobe Epilepsy